There are many forms of autoimmune disease, but by definition they all have one thing in common—they arise when the body's immunological defenses go awry and attack our cells or trigger biochemical changes that lead to ...
Jan 25, 2023
0
11
A number of new neurologic medications for diseases like multiple sclerosis (MS), Parkinson's disease and migraine have received U.S. Food and Drug Administration (FDA) approval over the past decade. However, with most having ...
Nov 30, 2022
0
2
Early intervention with rituximab, a drug used in the treatment of rheumatoid arthritis (RA), can reduce the risk of deterioration in myasthenia gravis, an autoimmune disease that causes loss of muscle control. This is according ...
Sep 19, 2022
0
48
Autoimmune diseases occur when a person's antibodies mistakenly recognize their body's own cells as foreign invaders and attack them. One such disease is myasthenia gravis (MG), where the antibodies target neuromuscular-associated ...
Jul 28, 2022
0
86
COVID-19 positive outpatients are at an increased risk of neurodegenerative disorders compared with individuals who tested negative for the virus, a new study presented today at the 8th European Academy of Neurology (EAN) ...
Jun 24, 2022
0
2249
Argenx SE, a Belgian drug maker, recently announced interim results from ADAPT+, an ongoing Phase 3, open-label, three-year extension study evaluating long-term safety, tolerability and efficacy of VYVGART (efgartigimod alfa-fcab) ...
Apr 7, 2022
0
4
(HealthDay)—Vyvgart (efgartigimod), a neonatal Fc receptor blocker (FcRn), was approved to treat generalized myasthenia gravis in adults who test positive for the anti-acetylcholine receptor (AChR) antibody, the U.S. Food ...
Dec 21, 2021
0
6
Argenx, a Belgium pharmaceutical company, recently announced that The Lancet Neurology has published pivotal trial results from the Phase 3 ADAPT trial of efgartigimod, an FcRn antagonist, for the treatment of adults living ...
Jun 18, 2021
0
3
(HealthDay)—In new evidence-based clinical guidelines published in the May 7 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report, recommendations are presented for diagnosing, ...
May 19, 2021
0
2
A study of 181 patients at 16 sites across the country who test negative for two antibodies long known to cause muscle-weakening myasthenia gravis, found that about 15% test positive for one of two newly discovered antibodies ...
Aug 19, 2020
0
5
